A radioprotector: cysteamine, inhibits oxygen transport in lipidic membranes. 1987

A Vachon, and V Roman, and C Lecomte, and G Folcher, and M Fatôme, and P Braquet, and F Berleur
Commissariat à l'Energie Atomique, IRDI/DESICP/DPC/SCM CEN Saclay, Gif-sur-Yvette, France.

Spin labeling techniques make possible the observation of oxygen diffusion or concentrations in phospholipid membranes. In such a system, cysteamine, depending upon the molecular cysteamine/DPPC ratio and the pH conditions, inhibits oxygen transport, and this result provides an original explanation for cellular hypoxia after cysteamine administration.

UI MeSH Term Description Entries
D008567 Membranes, Artificial Artificially produced membranes, such as semipermeable membranes used in artificial kidney dialysis (RENAL DIALYSIS), monomolecular and bimolecular membranes used as models to simulate biological CELL MEMBRANES. These membranes are also used in the process of GUIDED TISSUE REGENERATION. Artificial Membranes,Artificial Membrane,Membrane, Artificial
D010100 Oxygen An element with atomic symbol O, atomic number 8, and atomic weight [15.99903; 15.99977]. It is the most abundant element on earth and essential for respiration. Dioxygen,Oxygen-16,Oxygen 16
D010743 Phospholipids Lipids containing one or more phosphate groups, particularly those derived from either glycerol (phosphoglycerides see GLYCEROPHOSPHOLIPIDS) or sphingosine (SPHINGOLIPIDS). They are polar lipids that are of great importance for the structure and function of cell membranes and are the most abundant of membrane lipids, although not stored in large amounts in the system. Phosphatides,Phospholipid
D011837 Radiation-Protective Agents Drugs used to protect against ionizing radiation. They are usually of interest for use in radiation therapy but have been considered for other purposes, e.g. military. Radiation Protectant,Radiation Protective Agent,Radiation-Protective Agent,Radiation-Protective Drug,Radioprotective Agent,Radioprotective Agents,Radioprotective Drug,Agents, Radiation-Protective,Radiation Protectants,Radiation Protective Agents,Radiation-Protective Drugs,Radiation-Protective Effect,Radiation-Protective Effects,Radioprotective Drugs,Agent, Radiation Protective,Agent, Radiation-Protective,Agent, Radioprotective,Agents, Radiation Protective,Agents, Radioprotective,Drug, Radiation-Protective,Drug, Radioprotective,Drugs, Radiation-Protective,Drugs, Radioprotective,Effect, Radiation-Protective,Effects, Radiation-Protective,Protectant, Radiation,Protectants, Radiation,Protective Agent, Radiation,Protective Agents, Radiation,Radiation Protective Drug,Radiation Protective Drugs,Radiation Protective Effect,Radiation Protective Effects
D003543 Cysteamine A mercaptoethylamine compound that is endogenously derived from the COENZYME A degradative pathway. The fact that cysteamine is readily transported into LYSOSOMES where it reacts with CYSTINE to form cysteine-cysteamine disulfide and CYSTEINE has led to its use in CYSTINE DEPLETING AGENTS for the treatment of CYSTINOSIS. Cysteinamine,Mercaptamine,2-Aminoethanethiol,Becaptan,Cystagon,Cysteamine Bitartrate,Cysteamine Dihydrochloride,Cysteamine Hydrobromide,Cysteamine Hydrochloride,Cysteamine Maleate (1:1),Cysteamine Tartrate,Cysteamine Tartrate (1:1),Cysteamine Tosylate,Cysteamine, 35S-Labeled,Mercamine,Mercaptoethylamine,beta-Mercaptoethylamine,2 Aminoethanethiol,35S-Labeled Cysteamine,Bitartrate, Cysteamine,Cysteamine, 35S Labeled,Dihydrochloride, Cysteamine,Hydrobromide, Cysteamine,Hydrochloride, Cysteamine,Tartrate, Cysteamine,Tosylate, Cysteamine,beta Mercaptoethylamine
D001692 Biological Transport The movement of materials (including biochemical substances and drugs) through a biological system at the cellular level. The transport can be across cell membranes and epithelial layers. It also can occur within intracellular compartments and extracellular compartments. Transport, Biological,Biologic Transport,Transport, Biologic

Related Publications

A Vachon, and V Roman, and C Lecomte, and G Folcher, and M Fatôme, and P Braquet, and F Berleur
January 1981, Physiological chemistry and physics,
A Vachon, and V Roman, and C Lecomte, and G Folcher, and M Fatôme, and P Braquet, and F Berleur
January 1988, Physiological chemistry and physics and medical NMR,
A Vachon, and V Roman, and C Lecomte, and G Folcher, and M Fatôme, and P Braquet, and F Berleur
February 2003, Journal of agricultural and food chemistry,
A Vachon, and V Roman, and C Lecomte, and G Folcher, and M Fatôme, and P Braquet, and F Berleur
January 1998, Advances in experimental medicine and biology,
A Vachon, and V Roman, and C Lecomte, and G Folcher, and M Fatôme, and P Braquet, and F Berleur
December 2020, Membranes,
A Vachon, and V Roman, and C Lecomte, and G Folcher, and M Fatôme, and P Braquet, and F Berleur
January 1976, Tsitologiia,
A Vachon, and V Roman, and C Lecomte, and G Folcher, and M Fatôme, and P Braquet, and F Berleur
August 1996, Biochemical and biophysical research communications,
A Vachon, and V Roman, and C Lecomte, and G Folcher, and M Fatôme, and P Braquet, and F Berleur
May 1970, Experientia,
A Vachon, and V Roman, and C Lecomte, and G Folcher, and M Fatôme, and P Braquet, and F Berleur
November 1990, Radiation research,
A Vachon, and V Roman, and C Lecomte, and G Folcher, and M Fatôme, and P Braquet, and F Berleur
August 1989, Xenobiotica; the fate of foreign compounds in biological systems,
Copied contents to your clipboard!